In this episode, TRC Healthcare editor, Sara Klockars, PharmD, BCPS unpacks the newly approved use of tirzepatide (Zepbound) for obstructive sleep apnea (OSA)—a first-in-class pharmacologic option for a condition long managed with devices and lifestyle changes.
You’ll hear a concise review of sleep apnea pathophysiology, how tirzepatide works to reduce airway obstruction, and what the latest clinical trials reveal about its efficacy and safety. Plus, you’ll get practical pharmacy-focused insights on side effect management, payer considerations, and how to avoid duplicate GLP-1 therapy.
This is an excerpt from our April 2025 Pharmacy Essential Updates continuing education webinar series.
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:
Don’t miss out! Subscribe today to stay ahead with trusted insights and tools.
Use code podcast1025 at checkout for 10% off a new subscription.
🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.
****
GLP-1 Essentials from TRC Healthcare – Now Available
Master the essentials of GLP-1 therapy with this focused GLP-1 agonists CE bundle. Get 4 hours of CE plus clinical tools to help you prescribe, titrate, switch therapies, and support patients confidently.
Courses include:
Now included with Pharmacist’s Letter Platinum and Diamond subscriptions, or available as a standalone CE experience.
****
****
Join the National Community Pharmacists Associations’ Annual Convention (NCPA) in New Orleans October 18-21st: https://bit.ly/ncpameeting25
****
If you’re not yet a subscriber, find out more about our product offerings at trchealthcare.com.
Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.
